Dimerix Ltd
ASX:DXB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.35
0.755
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Dimerix Ltd
ASX:DXB
|
317.2m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.6B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
46.9B USD |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Dimerix Ltd
Glance View
Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Dimerix Ltd is -524.3%, which is above its 3-year median of -16 204.4%.
Over the last 3 years, Dimerix Ltd’s Operating Margin has increased from -435 162.5% to -524.3%. During this period, it reached a low of -435 162.5% on May 30, 2022 and a high of -524.3% on Jul 30, 2025.